tirzepatide hi High Dose Programs changing treatment that can accelerate your weight loss journey and help you achieve lasting results. New Weight Loss Medical Advances.
Description
For example, the benefits for overweight/obese individuals were highlighted in the SURMOUNT-1 trial, which involved overweight/obese individuals with an average weight of 104.8 kg and a BMI of 38.0, indicating that tirzepatide could be a new option for weight loss in this specific population
Gradual dose titration, as recommended in the prescribing information, helps minimize these effects
Visit our website, give us a call, or schedule a consultation for more information
Tirzepatide a newer dual-action GIP + GLP-1 agonist showing the highest average weight reduction in studies
Research shows semaglutide may be more effective than dulaglutide for weight loss in people with type 2 diabetes
